The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
Hirashima T, Kanai T, Suzuki H, Yoshida H, Matsushita A, Kawasumi H, Samejima Y, Noda Y, et al. (16 authors)
Anticancer research · 2019-11
Abstract
Background/aim The present study aimed to prospectively examine the usefulness of interferon-gamma (IFN-γ) release (IGR) as a biomarker in non-small-cell lung cancer patients receiving immune checkpoint inhibitor treatment (ICI-Tx). Patients and methods IGR was measured using enzyme-linked immunosorbent assay at four time points: within 14 days before ICI-Tx (T1), and 8±3 (T2), 22±7 (T3), and 43±7 (T4) days after ICI-Tx. Results Twenty-nine patients were divided into three groups based on IFN-γ levels in the IGR-positive control: Group-1 (n=8) with Conclusion IFN-γ levels could be a biomarker for ICI-Tx.
MeSH terms
- T-Lymphocytes
- Humans
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Lung Diseases, Interstitial
- Disease Progression
- Antibodies, Monoclonal
- Immunotherapy
- Prospective Studies
- Time Factors
- Adult
- Aged
- Aged, 80 and over
- Middle Aged
- Female
- Male
- Interferon-gamma
- Latent Tuberculosis
- Antibodies, Monoclonal, Humanized
- Biomarkers, Tumor
- Antineoplastic Agents, Immunological
- B7-H1 Antigen
- Nivolumab